The thought was so tantalizing. Medication within the GLP-1 class, which incorporates Wegovy and Ozempic, have proved miraculous in treating weight reduction and different ailments. And a few researchers hoped that the medicine may additionally assist with a number of the most troublesome ailments to deal with — these of the mind, like Parkinson’s.
However now, not less than for Parkinson’s, that hope appears dimmed. A rigorous research that randomly assigned Parkinson’s sufferers to take exenatide, a relative of Ozempic, confirmed completely no profit or slowing of the course of the degenerative illness after 96 weeks.
And there have been no impact on affected person signs, no impact on mind scans, no subgroup that confirmed any profit. Regardless of how the researchers sliced the info the outcomes had been the identical.
The research, revealed Tuesday in The Lancet, is unhealthy information for the half million Individuals who’ve been recognized with Parkinson’s illness. Signs embody tremors, stiffness and problem with stability. Sufferers additionally might develop dementia. Therapies, together with medicines and deep mind stimulation, may also help with signs. However no therapy has been proven to gradual the illness’s progress.
“It’s vastly disappointing,” stated Dr. Thomas Foltynie of College Faculty London, who led the trial. “We had been anticipating we might come by and we’d get a optimistic end result.”
Parkinson’s specialists shared his sentiment.
“It is a sobering second,” stated Dr. Michael S. Okun, a Parkinson’s illness professional on the College of Florida and the nationwide medical adviser for the Parkinson’s Basis. “It is a very well achieved research and it got here up empty-handed.”
The discovering might have implications for researchers who’re asking if the newer GLP-1 medicine may assist gradual the course of Alzheimer’s or may stop the illness.
The brand new research concerned 194 folks with Parkinson’s illness handled at six analysis hospitals within the U.Ok. The sufferers had been randomly assigned to inject themselves as soon as per week for 96 weeks with exenatide, a sort 2 diabetes therapy made by AstraZeneca and bought below the model identify Byetta, or with a placebo. The trial was funded by Britain’s Nationwide Institute for Well being and Care Analysis with help for substudies from the charity Remedy Parkinson’s and the Van Andel Institute.
The drug is in the identical class as Ozempic and Wegovy and, like them, lowers blood sugar ranges. All are so-called GLP-1 receptor agonists, generally referred to as GLP-1s. Exenatide isn’t as highly effective in eliciting weight reduction because the newer medicine, however specialists say there isn’t any purpose to imagine that the more moderen medicine would carry out in another way in research of mind illness.
The outcomes, researchers stated, are particularly disappointing as a result of there have been ideas that GLP-1 medicine may assist Parkinson’s sufferers.
GLP-1 medicine protected neurons from injury in laboratory research and in a research with rats given a mind damage like that in Parkinson’s illness.
It started to appear that the outcomes may additionally apply to sufferers.
“Individuals began digging into claims databases,” Dr. Okun stated, explaining that researchers had examined massive databases displaying medicine that individuals took and their diagnoses. The researchers requested if sufferers who had taken GLP-1s may be much less prone to get Parkinson’s or, if that they had it, would have a illness that progressed extra slowly.
The outcomes had been promising.
They regarded at epidemiological research. They discovered that individuals with diabetes who took GLP-1s had been much less prone to have Parkinson’s.
Then two small research instructed that exenatide may gradual the development of some Parkinson’s signs over a 12 months’s time.
Persevering with the hints of progress, a bigger however nonetheless preliminary research, revealed final 12 months within the New England Journal of Medication, discovered {that a} GLP-1 that’s not in the marketplace — lixisenatide — appeared to barely gradual progress of the illness over a 12 months.
Dr. Okun, on the time, stated that the end result was “nibbling on the edges of illness modification.”
“What we had final 12 months was a one-year trial and a small sign,” stated Dr. David Standaert, a Parkinson’s researcher on the College of Alabama at Birmingham. “What would occur should you went longer? Effectively, that is longer and there’s simply not a lot right here.”
The issue with learning GLP-1s in Parkinson’s illness, Dr. Standaert stated, is that what exenatide is meant to be doing within the mind isn’t clear.
“I wouldn’t do one other research like this until you study what’s the goal,” Dr. Standaert stated. “What’s the biochemistry you are attempting to alter within the mind? How do these medicine work, anyway?”
